Matthew T. Burger

Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor

Sauveur-Michel Maira, Sabina Pecchi, Alan Huang et al. · Molecular Cancer Therapeutics · 2011 · 524 citations

Pharmacotherapy, Different Selectivity Profile, Chemical Biology +26

Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer

Matthew T. Burger, Sabina Pecchi, Allan S. Wagman et al. · ACS Medicinal Chemistry Letters · 2011 · 248 citations · Full text

2,4-Bismorpholino 6-Heterocyclic Pyrimidines, Pi3 Kinase Inhibitor, Orally Bioavailable Class +18

Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers

Pablo D. García, John L. Langowski, Yingyun Wang et al. · Clinical Cancer Research · 2014 · 110 citations · Full text

Enantioselective Recognition by a New Chiral Stationary Phase at the Receptor Level

Francesco Gasparrini, Domenico Misiti, Claudio Villani et al. · The Journal of Organic Chemistry · 1995 · 84 citations

Identification of <i>N</i>-(4-((1<i>R</i>,3<i>S</i>,5<i>S</i>)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies

Matthew T. Burger, Gisele Nishiguchi, Wooseok Han et al. · Journal of Medicinal Chemistry · 2015 · 72 citations · Full text

Hematological Malignancy, Moloney Murine Leukemia, Medicinal Chemistry +14